2 weeks Ago By ABMN Staff
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY – Free Report ) – Analysts at Zacks Research upped their FY2026 EPS estimates for Alnylam Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 24th. Zacks Research analyst A.
Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $2.15 for the year, up from their prior forecast of $2.11.
The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.73) per share. Other research analysts also recently issued research reports about the stock.
JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.
00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $291.00 to $342.
00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.
00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.
00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the stock from $198.00 to $370.
00 in a report on Friday, August 16th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.
com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.14. Alnylam Pharmaceuticals Stock Performance ALNY stock opened at $274.
91 on Friday. The firm has a market capitalization of $34.77 billion, a price-to-earnings ratio of -102.
58 and a beta of 0.38. The firm has a 50 day moving average price of $263.
00 and a 200-day moving average price of $203.01. Alnylam Pharmaceuticals has a 52-week low of $141.
98 and a 52-week high of $287.55. Alnylam Pharmaceuticals ( NASDAQ:ALNY – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st.
The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.
61. The company had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.
22 million. During the same period in the previous year, the firm posted ($2.21) earnings per share.
The firm’s revenue for the quarter was up 107.0% compared to the same quarter last year. Institutional Investors Weigh In On Alnylam Pharmaceuticals A number of institutional investors and hedge funds have recently bought and sold shares of ALNY.
Allspring Global Investments Holdings LLC grew its position in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter.
Ashton Thomas Private Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $26,000. Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $30,000.
V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $52,000. Finally, Prestige Wealth Management Group LLC raised its stake in Alnylam Pharmaceuticals by 69.8% in the 1st quarter.
Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 194 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets In other news, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.
00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,168,101. The transaction was disclosed in a document filed with the SEC, which is available at this link .
In other news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.
00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at $35,632.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.
00, for a total value of $1,851,273.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,168,101.
The disclosure for this sale can be found here . Over the last quarter, insiders have sold 57,491 shares of company stock worth $15,446,733. Insiders own 1.
50% of the company’s stock. Alnylam Pharmaceuticals Company Profile ( Get Free Report ) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Articles Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
